MedTrace Logo

A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

NCT05727267 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-04-24

No results posted yet for this study

Summary

This study is an open-label, ascending dose phase 1a trial to assess the safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine

Conditions

Interventions

BIOLOGICAL

HEPLISAV B; TherVacB

Administration of the described combinations via the intramuscular route

BIOLOGICAL

TherVacB

Administration of the described combinations via the intramuscular route

Sponsors & Collaborators

  • German Center for Infection Research

    collaborator OTHER

  • Medical Biometry and Epidemiology_- Universitätsklinikum Hamburg Eppendorf

    collaborator UNKNOWN

  • Helmholtz Zentrum München

    collaborator INDUSTRY

  • The Fraunhofer-Gesellschaft

    collaborator OTHER

  • Institute of Virology Helmholtz Zentrum München (HMGU)

    collaborator UNKNOWN

  • LMU Klinikum

    collaborator OTHER

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Principal Investigators

  • Marylyn M Addo, Prof · Universitätsklinikum Hamburg-Eppendorf

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-23
Primary Completion
2026-02-28
Completion
2026-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05727267 on ClinicalTrials.gov